跳转至内容
Merck
CN

I0060000

异环磷酰胺

European Pharmacopoeia (EP) Reference Standard

登录查看公司和协议定价

别名:
Ifex, N,3-双(2-氯乙基)四氢-2H-1,3,2-氧杂磷烷基-2-胺-2-氧化物
经验公式(希尔记法):
C7H15Cl2N2O2P
CAS号:
分子量:
261.09
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

ifosfamide

制造商/商品名称

EDQM

技术

HPLC: suitable
gas chromatography (GC): suitable

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

ClCCNP1(=O)OCCCN1CCCl

InChI

1S/C7H15Cl2N2O2P/c8-2-4-10-14(12)11(6-3-9)5-1-7-13-14/h1-7H2,(H,10,12)

InChI key

HOMGKSMUEGBAAB-UHFFFAOYSA-N

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Ifosfamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

异环磷酰胺是一种氮芥类化合物,是环磷酰胺的结构异构体。 异环磷酰胺是一种前药,必须通过细胞色素P450转化为生物活性成分。 它在癌症化疗中可用作抗肿瘤药,但是异环磷酰胺比环磷酰胺更可能引起肾毒性。

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Skull and crossbonesHealth hazard

警示用语:

Danger

危险分类

Acute Tox. 3 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Repr. 1B

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Priti N Patel
The Annals of pharmacotherapy, 40(2), 299-303 (2006-01-05)
To evaluate the use of methylene blue for the treatment of ifosfamide-induced encephalopathy. MEDLINE (1966-August 2005) and International Pharmaceutical Abstracts (1971-August 2005) were searched using the terms methylene blue, ifosfamide, encephalopathy, and neurotoxicity. Several case reports and one retrospective chart
Kjetil Boye et al.
Pediatric blood & cancer, 61(5), 840-845 (2013-11-21)
Patients with metastatic osteosarcoma at diagnosis or axial primary tumors have a poor prognosis. The aim of the study was to evaluate the feasibility and efficacy of intensified treatment with high-dose chemotherapy (HDCT) and stem cell rescue in this group.
Yesne Alici-Evcimen et al.
Psycho-oncology, 16(10), 956-960 (2007-02-06)
Ifosfamide is a chemotherapy agent commonly used in the treatment of several solid tumors and hematologic malignancies. Common ifosfamide toxicities are bone marrow suppression, alopecia, nausea and vomiting. Less common, but striking, are the rare but dramatic neuropsychiatric toxicities with
Elham Amini et al.
Pediatric blood & cancer, 51(1), 137-140 (2008-03-14)
A 5-year-old male presented with spinal cord drop metastasis from a recurrent neurocytoma. Topotecan (0.5 mg/m(2)) and carboplatin (250 mg/m(2)) were administered on days 1-3 and ifosfamide (1,800 mg/m(2)) on days 1-5, every 21 days, for three cycles and resulted
Karen I Sweiss et al.
Drug safety, 31(11), 989-996 (2008-10-09)
Encephalopathy occurs in 10-40% of patients treated with high-dose ifosfamide. Proposed risk factors for encephalopathy include hepatic or renal dysfunction, brain metastases, electrolyte imbalances and drug-drug interactions. The purpose of this retrospective cohort study and literature review was to estimate

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门